171 related articles for article (PubMed ID: 28184434)
1. Tell-Tale SNPs: The Role of CYP2B6 in Methadone Fatalities.
Ahmad T; Sabet S; Primerano DA; Richards-Waugh LL; Rankin GO
J Anal Toxicol; 2017 May; 41(4):325-333. PubMed ID: 28184434
[TBL] [Abstract][Full Text] [Related]
2. Contribution of CYP2B6 alleles in explaining extreme (S)-methadone plasma levels: a CYP2B6 gene resequencing study.
Dobrinas M; Crettol S; Oneda B; Lahyani R; Rotger M; Choong E; Lubomirov R; Csajka C; Eap CB
Pharmacogenet Genomics; 2013 Feb; 23(2):84-93. PubMed ID: 23249875
[TBL] [Abstract][Full Text] [Related]
3. Methadone enantiomer plasma levels, CYP2B6, CYP2C19, and CYP2C9 genotypes, and response to treatment.
Crettol S; Déglon JJ; Besson J; Croquette-Krokkar M; Gothuey I; Hämmig R; Monnat M; Hüttemann H; Baumann P; Eap CB
Clin Pharmacol Ther; 2005 Dec; 78(6):593-604. PubMed ID: 16338275
[TBL] [Abstract][Full Text] [Related]
4. CYP2B6 SNPs are associated with methadone dose required for effective treatment of opioid addiction.
Levran O; Peles E; Hamon S; Randesi M; Adelson M; Kreek MJ
Addict Biol; 2013 Jul; 18(4):709-16. PubMed ID: 21790905
[TBL] [Abstract][Full Text] [Related]
5. Combined Effect of CYP2B6 Genotype and Other Candidate Genes on a Steady-State Serum Concentration of Methadone in Opioid Maintenance Treatment.
Kringen MK; Chalabianloo F; Bernard JP; Bramness JG; Molden E; Høiseth G
Ther Drug Monit; 2017 Oct; 39(5):550-555. PubMed ID: 28723731
[TBL] [Abstract][Full Text] [Related]
6. Methadone Pharmacogenetics: CYP2B6 Polymorphisms Determine Plasma Concentrations, Clearance, and Metabolism.
Kharasch ED; Regina KJ; Blood J; Friedel C
Anesthesiology; 2015 Nov; 123(5):1142-53. PubMed ID: 26389554
[TBL] [Abstract][Full Text] [Related]
7. Differences in Methadone Metabolism by CYP2B6 Variants.
Gadel S; Friedel C; Kharasch ED
Drug Metab Dispos; 2015 Jul; 43(7):994-1001. PubMed ID: 25897175
[TBL] [Abstract][Full Text] [Related]
8. Impact of ABCB1 and CYP2B6 genetic polymorphisms on methadone metabolism, dose and treatment response in patients with opioid addiction: a systematic review and meta-analysis.
Dennis BB; Bawor M; Thabane L; Sohani Z; Samaan Z
PLoS One; 2014; 9(1):e86114. PubMed ID: 24489693
[TBL] [Abstract][Full Text] [Related]
9. Effects of cytochrome P450 single nucleotide polymorphisms on methadone metabolism and pharmacodynamics.
Ahmad T; Valentovic MA; Rankin GO
Biochem Pharmacol; 2018 Jul; 153():196-204. PubMed ID: 29458047
[TBL] [Abstract][Full Text] [Related]
10. Methadone pharmacogenetics in vitro and in vivo: Metabolism by CYP2B6 polymorphic variants and genetic variability in paediatric disposition.
Wang PF; Sharma A; Montana M; Neiner A; Juriga L; Reddy KN; Tallchief D; Blood J; Kharasch ED
Br J Clin Pharmacol; 2022 Nov; 88(11):4881-4893. PubMed ID: 35538637
[TBL] [Abstract][Full Text] [Related]
11. Fatal methadone toxicity: potential role of CYP3A4 genetic polymorphism.
Richards-Waugh LL; Primerano DA; Dementieva Y; Kraner JC; Rankin GO
J Anal Toxicol; 2014 Oct; 38(8):541-7. PubMed ID: 25217544
[TBL] [Abstract][Full Text] [Related]
12. CYP2B6 polymorphisms influence the plasma concentration and clearance of the methadone S-enantiomer.
Wang SC; Ho IK; Tsou HH; Tian JN; Hsiao CF; Chen CH; Tan HK; Lin L; Wu CS; Su LW; Huang CL; Yang YH; Liu ML; Lin KM; Chen CY; Liu SC; Wu HY; Chan HW; Tsai MH; Lin PS; Liu YL
J Clin Psychopharmacol; 2011 Aug; 31(4):463-9. PubMed ID: 21694616
[TBL] [Abstract][Full Text] [Related]
13. Implications of OPRM1 and CYP2B6 variants on treatment outcomes in methadone-maintained patients in Ontario: Exploring sex differences.
Chawar C; Hillmer A; Lamri A; Kapczinski F; Thabane L; Pare G; Samaan Z
PLoS One; 2021; 16(12):e0261201. PubMed ID: 34910759
[TBL] [Abstract][Full Text] [Related]
14. Relationship between CYP2B6*6 and cold pressor pain sensitivity in opioid dependent patients on methadone maintenance therapy (MMT).
Zahari Z; Lee CS; Ibrahim MA; Musa N; Mohd Yasin MA; Lee YY; Tan SC; Mohamad N; Ismail R
Drug Alcohol Depend; 2016 Aug; 165():143-50. PubMed ID: 27289271
[TBL] [Abstract][Full Text] [Related]
15. Novel associations between
Packiasabapathy S; Aruldhas BW; Zhang P; Overholser BR; Quinney SK; Sadhasivam S
Pharmacogenomics; 2021 Jul; 22(10):591-602. PubMed ID: 34100292
[No Abstract] [Full Text] [Related]
16. Pharmacogenomics biomarkers for personalized methadone maintenance treatment: The mechanism and its potential use.
Ramli FF
Bosn J Basic Med Sci; 2021 Apr; 21(2):145-154. PubMed ID: 32841585
[TBL] [Abstract][Full Text] [Related]
17. Investigating the CYP2B6 rs3745274 and rs3211371 polymorphisms in Methadone-Responder and Non-Responder Addicts in Iran.
Sadat Aghabozorg Afjeh S; Boshehri B; Hamednia S; Amini A; Mashayekhi P; Omrani MD
Iran Biomed J; 2021 Feb; 25(3):220-5. PubMed ID: 33546554
[TBL] [Abstract][Full Text] [Related]
18. Relevance of CYP2B6 and CYP2D6 genotypes to methadone pharmacokinetics and response in the OPAL study.
Victorri-Vigneau C; Verstuyft C; Bouquié R; Laforgue EJ; Hardouin JB; Leboucher J; Le Geay B; Dano C; Challet-Bouju G; Grall-Bronnec M
Br J Clin Pharmacol; 2019 Jul; 85(7):1538-1543. PubMed ID: 30907440
[TBL] [Abstract][Full Text] [Related]
19. Toward precision prescribing for methadone: Determinants of methadone deposition.
Talal AH; Ding Y; Venuto CS; Chakan LM; McLeod A; Dharia A; Morse GD; Brown LS; Markatou M; Kharasch ED
PLoS One; 2020; 15(4):e0231467. PubMed ID: 32302325
[TBL] [Abstract][Full Text] [Related]
20. Stereoselective block of hERG channel by (S)-methadone and QT interval prolongation in CYP2B6 slow metabolizers.
Eap CB; Crettol S; Rougier JS; Schläpfer J; Sintra Grilo L; Déglon JJ; Besson J; Croquette-Krokar M; Carrupt PA; Abriel H
Clin Pharmacol Ther; 2007 May; 81(5):719-28. PubMed ID: 17329992
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
